Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism
- 1 December 2020
- journal article
- letter
- Published by Elsevier BV in Thrombosis Research
- Vol. 196, 367-370
- https://doi.org/10.1016/j.thromres.2020.09.008
Abstract
No abstract availableFunding Information
- The Permanente Medical Group's Central Research Committee
- Kaiser Permanente Pharmacy Department
This publication has 12 references indexed in Scilit:
- Apixaban for the Treatment of Venous Thromboembolism Associated with CancerThe New England Journal of Medicine, 2020
- Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral AnticoagulantsPublished by Springer Science and Business Media LLC ,2019
- Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)Journal of Clinical Oncology, 2018
- Edoxaban for the Treatment of Cancer-Associated Venous ThromboembolismThe New England Journal of Medicine, 2018
- Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trialJournal of Thrombosis and Haemostasis, 2015
- Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-AnalysisPLoS Medicine, 2012
- Outpatient Use of Low Molecular Weight Heparin Monotherapy for First-Line Treatment of Venous Thromboembolism in Advanced CancerThe Oncologist, 2012
- Barriers to the long‐term use of low‐molecular weight heparins for treatment of cancer‐associated thrombosisJournal of Thrombosis and Haemostasis, 2006
- Building a Virtual Cancer Research OrganizationJNCI Monographs, 2005
- Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with CancerThe New England Journal of Medicine, 2003